Clinical Trial Update: XPO-1 in Combination With RCHOP for DH/TH Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating XPO-1 in combination with RCHOP for double hit and triple hit lymphoma is ongoing, with status currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Double-hit Lymphoma
• Triple-hit Lymphoma

Drugs mentioned

• RCHOP (rituximab cyclophosphamide doxorubicin vincristine prednisone)
• XPO-1

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Double Hit Lymphoma, Triple Hit Lymphoma | Phase 2 | Status: UNKNOWN